Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blepharitis Clear all
Completed Phase 4 Interventional Results available

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

NCT01478256
View directory record Official record
Conditions
Blepharitis
Interventions
Erythromycin, Besifloxocin
Drug
Lead sponsor
John, George, M.D.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

NCT01543490
View directory record Official record
Conditions
Active, Symptomatic Blepharitis
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
1 Year and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 21, 2026, 9:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease

NCT00355459
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Tetracycline: Doxycycline analog
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 21, 2026, 9:32 AM EDT
Terminated Not applicable Interventional

Ocular Comfort and Inflammation in Lid Hygiene Therapy

NCT02938078
View directory record Official record
Conditions
Blepharitis
Interventions
Avenova Lid Cleanser
Device
Lead sponsor
Minnesota Eye Consultants, P.A.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 21, 2026, 9:32 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

NCT06054217
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Results available

Demodex Blepharitis Treatment Study

NCT01647217
View directory record Official record
Conditions
Chronic Blepharitis
Interventions
Terpinen-4-ol, Placebo
Drug · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
15 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04784091
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Northridge, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

NCT03926026
View directory record Official record
Conditions
Blepharitis
Interventions
Fluticasone Propionate, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

NCT00892970
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Little Rock, Arkansas • Artesia, California • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 21, 2026, 9:32 AM EDT
Not listed Not applicable Interventional

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

NCT02455895
View directory record Official record
Conditions
Sebaceous Gland Diseases, Blepharitis
Interventions
iLid Cleanser
Device
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • San Leandro, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998
View directory record Official record
Conditions
Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions
AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

NCT01408082
View directory record Official record
Conditions
Blepharitis
Interventions
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

NCT00629590
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wantagh, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 21, 2026, 9:32 AM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Corneal and External Diseases

NCT00008541
View directory record Official record
Conditions
Blepharitis, Conjunctivitis, Corneal Disease, Dacryoadenitis, Dacryocystitis, Keratitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

NCT06795165
View directory record Official record
Conditions
Blepharitis
Interventions
Moxidectin 2 MG Oral Tablet, Placebo
Drug
Lead sponsor
Eye Research Foundation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

NCT00345241
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2008 · Synced Jul 21, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

NCT07400965
View directory record Official record
Conditions
Demodex Blepharitis
Interventions
GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020
View directory record Official record
Conditions
Corneal Infiltrates
Interventions
Moxifloxacin/dexamethasone phosphate ophthalmic solution, Moxifloxacin ophthalmic solution 0.5%, Dexamethasone phosphate solution, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

NCT00629980
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Artesia, California • Mission Hills, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 21, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

NCT04675242
View directory record Official record
Conditions
Blepharitis
Interventions
NCX 4251, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511
View directory record Official record
Conditions
Blepharitis
Interventions
Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment
Drug
Lead sponsor
Famy Life Sciences, a Viatris Company
Industry
Eligibility
2 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 9:32 AM EDT